Rasagiline

Generic Name: Rasagiline

Brand Names: Azilect, Rasagiline Mylan, Rasagiline ratiopharm

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₃N

CAS Number: 136236-51-6

Unique Ingredient Identifier: 003N66TS6T

Background: Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Indication: For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.

Associated Conditions: Parkinson's Disease (PD)

Clinical Trials

Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease

Phase 4

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Rasagiline

First Posted Date: 2010-08-09

Last Posted Date: 2012-10-04

Lead Sponsor: University of Zurich

Target Recruit Count: 1

Registration Number: NCT01178047

Locations: 🇨🇭
University Hospital, Neurology, Zurich, ZH, Switzerland
🇨🇭
Neurocentro, Lugano, Lugano, Switzerland

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Rasagiline

First Posted Date: 2010-07-23

Last Posted Date: 2014-01-10

Lead Sponsor: University of Florida

Target Recruit Count: 30

Registration Number: NCT01168596

Locations: 🇺🇸
Shands and University of Florida Medical Plaza, Gainesville, Florida, United States
🇺🇸
University of Colorado Anschutz outpatient Pavilion, Aurora, Colorado, United States
🇺🇸
Cleveland Clinic Center for Neurological Restoration, Cleveland, Ohio, United States

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Preladenant 10 mg tablet
Drug: Placebo to Preladenant Tablet
Drug: Preladenant 2 mg tablet
Drug: Preladenant 5 mg tablet
Drug: Placebo to Rasagiline capsule
Drug: Rasagiline 1 mg capsule

First Posted Date: 2010-07-01

Last Posted Date: 2018-11-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 778

Registration Number: NCT01155466

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)

Phase 3

Terminated

Conditions: Parkinson Disease

Interventions: Drug: Preladenant 10 mg tablet
Drug: Preladenant 2 mg tablet
Drug: Preladenant 5 mg tablet
Drug: Rasagiline 1 mg capsule
Drug: Placebo for Preladenant
Drug: Placebo for Rasagiline 1 mg capsule

First Posted Date: 2010-07-01

Last Posted Date: 2018-11-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1022

Registration Number: NCT01155479

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

Phase 4

Completed

Conditions: Parkinson's Disease
Depressive Symptoms

Interventions: Drug: Rasagiline
Drug: Placebo

First Posted Date: 2010-01-25

Last Posted Date: 2021-08-31

Lead Sponsor: Lundbeck Italia S.p.A.

Target Recruit Count: 121

Registration Number: NCT01055379

Locations: 🇮🇹
IT001, Naples, Italy
🇮🇹
IT008, Rome, Italy
🇮🇹
IT015, Torino, Italy

and more 9 locations

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Rasagiline

First Posted Date: 2010-01-15

Last Posted Date: 2016-05-20

Lead Sponsor: Teva Neuroscience, Inc.

Target Recruit Count: 328

Registration Number: NCT01049984

Locations: 🇺🇸
Teva Investigational Site 21, Medford, Oregon, United States
🇺🇸
Teva Investigational Site 31, Charlotte, North Carolina, United States
🇺🇸
Teva Investigational Site 09, Richmond, Virginia, United States

and more 55 locations

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Phase 4

Terminated

Conditions: Early-stage Parkinson's Disease

Interventions: Drug: Pramipexole
Drug: Rasagiline

First Posted Date: 2010-01-13

Last Posted Date: 2012-05-28

Lead Sponsor: Qualissima

Target Recruit Count: 112

Registration Number: NCT01048229

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Rasagiline mesylate

First Posted Date: 2009-12-15

Last Posted Date: 2013-08-28

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 120

Registration Number: NCT01032486

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

Phase 4

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Rasagiline

First Posted Date: 2009-11-04

Last Posted Date: 2013-12-02

Lead Sponsor: The Parkinson's Institute

Target Recruit Count: 36

Registration Number: NCT01007630

Locations: 🇺🇸
The Parkinson's Institute, Sunnyvale, California, United States

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

Phase 2

Completed

Conditions: Multiple System Atrophy

Interventions: Drug: placebo
Drug: rasagiline mesylate

First Posted Date: 2009-09-16

Last Posted Date: 2015-02-26

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 174

Registration Number: NCT00977665

Locations: 🇺🇸
Teva Investigational Site 1004, Irvine, California, United States
🇺🇸
Teva Investigational Site 1006, Sunnyvale, California, United States
🇺🇸
Teva Investigational Site 1061, Boca Raton, Florida, United States

and more 44 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy